This study is looking at how a 12-week exercise program affects men with advanced prostate cancer that has spread (metastatic prostate adenocarcinoma). You could join if you are between 18 and 80 years old, male, and are currently taking hormone therapy (androgen deprivation therapy) alone or with other oral medications like abiraterone, enzalutamide, darolutamide, or apalutamide for at least three months. The main goal is to see if exercise can reduce the number of circulating tumor cells (CTCs) in your blood. The study aims to enroll 20 participants, but its current status is unclear.

Study design

This is a small, single-arm study, meaning all 20 participants will receive the exercise intervention. It is a pilot study to explore the effects of personalized exercise training.

What's involved

You would have initial screening, participate in a 12-week exercise program, and then have follow-up assessments 12 weeks after the exercise ends.

Compensation

Not stated in the trial record.

Follow-up

Your health records will be monitored for 365 days after the study completion to track your vital status.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.